A Novel Cost-effective Autologous Dermal Filler for Atrophic Acne Scar

Pol, Devayani; Kumar, Ajay; Deora, Mahendra Singh

doi:10.4103/idoj.idoj_128_20

Cited by 3 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are a number of clinical treatments for acne scarring, including pharmacological, surgical, and filler treatments 4,10–12 . Although favourable outcomes have been achieved, the treatment process is not without challenges; for example, with prolonged drug use, adverse reactions may occur and affect the therapeutic results.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, there are a number of clinical treatments for acne scarring, including pharmacological, surgical, and filler treatments. 4 , 10 , 11 , 12 Although favourable outcomes have been achieved, the treatment process is not without challenges; for example, with prolonged drug use, adverse reactions may occur and affect the therapeutic results. In recent years, better outcomes have been achieved in the treatment of depressed keloid scars by means of an ultra‐pulsed carbon dioxide fractional laser.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultrapulse carbon dioxide dot matrix laser for facial scar treatment: A meta‐analysis

Yan,

Sun,

et al. 2023

International Wound Journal

View full text Add to dashboard Cite

A meta‐analysis was performed to investigate the efficacy of ultrapulse carbon dioxide dot matrix laser treatment for patients with facial scars. PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, China Biomedical Literature Database, and Wanfang Database were systematically searched for randomised controlled trials (RCTs) investigating ultrapulse carbon dioxide dot matrix laser treatment for facial scars, and the search was conducted from the time of database inception to July 2023. The retrieved literature was screened independently by two researchers, and data extraction and quality assessments were performed. The meta‐analysis was conducted using RevMan 5.4 software. Outcome metrics included overall treatment effectiveness, complication rate, and Echelle d'évaluation clinique des cicatrices d'acné (ECCA) scores. Seventeen RCTs comprising 3703 patients were included, with 1853 patients in the experimental group and 1850 in the control group. The results showed that the experimental group had significantly increased overall treatment efficacy rates (odds ratio [OR]: 3.84, 95% confidence interval [CI]: 3.02–4.90, p < 0.001), reduced complication rates (OR: 0.35, 95% CI: 0.27–0.44, p < 0.001), and improved ECCA scores (standardised mean difference: −1.79, 95% CI: −2.53 to −1.05, p < 0.001) compared with the control group. In conclusion, as the primary treatment modality for facial acne depression scars, ultrapulse carbon dioxide dot matrix laser can significantly increase the overall treatment efficacy rate and ECCA scores and reduce the incidence of complications; however, higher‐quality studies are needed for further validation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ultrapulse carbon dioxide dot matrix laser for facial scar treatment: A meta‐analysis

Yan,

Sun,

et al. 2023

International Wound Journal

View full text Add to dashboard Cite

show abstract

Prospective Clinical Trial Demonstrating the Efficacy of Hyaluronic Acid Filler for the Improvement of Atrophic Facial Scars up to 2 years

Siperstein,

Nestor,

Meran

2024

Dermatol Surg

View full text Add to dashboard Cite

BACKGROUND Hyaluronic acid (HA) filler longevity has been studied for wrinkles. However, its long-term use for treating atrophic facial scars has not yet been analyzed in long-term prospective studies. OBJECTIVE Analyze the safety and duration of a HA filler for the use in atrophic scars. MATERIALS AND METHODS Fifteen subjects received VYC-17.5L in atrophic scars on 1 randomized cheek and saline on the other, with 1 optional touch-up treatment and crossover after the short-term trial. Grading for this long-term extension was done on Day 720, using the Global Aesthetic Improvement Scale (GAIS) and the Quantitative Global Scarring Grading System. RESULTS On Day 720, a live blind evaluator rated the VYC-17.5L assigned side as having significant reduction in scar severity (−7.2 [t(22) = −6.01, p = .00009]) and number of scars (−8.8 [t(22) = −6.25, p = .00006]) as compared with baseline. There was no significant difference in the results from Day 120 to Day 720. Ninety-two percent (11/12) of subjects reported improvement (GAIS), were satisfied with the treatment, thought it looked natural, and had fewer side effects than expected. There were no persistent or late-onset side effects. CONCLUSION VYC-17.5L improved rolling atrophic facial scars, and the results were sustained throughout the 2-year trial without side effects.

show abstract